Yourgene Health PLC (LON:YGEN) has said it is to develop its own proprietary coronavirus (COVID-19) test kit while it has also launched a service at its laboratories for private testing for the virus.
The AIM-listed group said it intends to launch a research-use only version of the Clarigene SARS-CoV-2 test by the end of June with a CE marked in vitro alternative to follow in July.
The Clarigene test is a molecular PCR based COVID-19 assay that is able to detect whether individuals are currently infected, it said.
Preliminary data for Clarigene shows competitive performance compared to other market-leading products, rapid turnaround time and low false-negative results, it added.
Yourgene said it will use its 300 laboratory customers and distribution channels to drive sales of Clarigene.
In a statement, Lyn Rees, Yourgene chief executive said: “The addition of the Clarigene infectious disease product portfolio strengthens our offering through our commercial channels and supports one of the strategic pillars of growth - our product diversification strategy."
The company recently signed a contract manufacturing agreement with Novacyt (LON:NYCT), another COVID-19 diagnostic test supplier, and said it intends to broaden its reach to private testing demand for specific populations such as UK GP surgeries, private clinics and companies.
Trading generally has stayed on track, Yourgene added, with its core molecular diagnostics business continuing to perform in line with management expectations.
The company said it remains confident of receiving a CE marking for its Illumina-based IONA test in the near future, adding it had been told it has been recommended for approval.
“It's especially pleasing to see that the main growth drivers of the business remain on track and with approval for our new Illumina platform NIPT just around the corner,” said Rees.